Brief: GenSight Biologics: Re-approval of FY 2022 Consolidated Financial Statements

Gensight Biologics SA

02/05/2023 06:56

May 2 (Reuters) - 
    Gensight Biologics SA  SIGHT.PA :
    * ANNOUNCED ON MONDAY BOARD OF DIRECTORS RE-APPROVED ITS
FULL YEAR
2022 CONSOLIDATED FINANCIAL STATEMENTS, AS UPDATED TO REFLECT
COMPANY'S RECENT DECISION TO WITHDRAW ITS EUROPEAN MEDICINES
AGENCY (EMA) APPLICATION FOR LUMEVOQ
    * FY 2022 FINANCIAL INFORMATION AS REPORTED BY COMPANY IN
ITS
PRESS RELEASE DATED MARCH 24, 2023, HAVE NOT CHANGED AS A RESULT
OF THE FULL YEAR 2022 CONSOLIDATED FINANCIAL STATEMENTS BEING
RE-APPROVED ON APRIL 28, 2023 
    * THESE CONSOLIDATED FINANCIAL STATEMENTS NOW INCLUDE
INFORMATION
IN NOTES TO FINANCIAL STATEMENTS TO REFLECT RECENT WITHDRAWAL OF
COMPANY'S APPLICATION WITH EMA AND ITS CHANGE IN CASH POSITION
AS DISCLOSED IN ITS PRESS RELEASES DATED APRIL 20, 2023, AND
APRIL 21, 2023, RESPECTIVELY

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nBw1JpnSBa
 Further company coverage:  SIGHT.PA  
   

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))